Articles

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer

Export this record

Export selected records

Export record to excel

File type to download

Beta version

Record title

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer

Record identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8288034

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer

ACCESS
https://collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8288034

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer

Full title

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer

Publisher

United States: Massachusetts Medical Society

Journal title

The New England journal of medicine, 2018, Vol.378 (26), p.2465-2474

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8288034

Language

English

Formats

Publication information

Publisher

United States: Massachusetts Medical Society

More information

SCOPE AND CONTENTS

Contents

In a trial, the median metastasis-free survival among men with nonmetastatic, castration-resistant prostate cancer and a short PSA doubling time was 36.6 months with enzalutamide and 14.7 months with placebo. Falls and heart problems were more common with enzalutamide.

ALTERNATIVE TITLES

Full title

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer

Identifiers

PRIMARY IDENTIFIERS

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8288034

Permalink

https://collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8288034

OTHER IDENTIFIERS

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1800536

How to access this item

Online

1 item

How to access?

Login with a Library card